Japan SAKIGAKE and pioneering designations: who holds them and why it matters
SAKIGAKE (Japanese for "forerunner") is the Ministry of Health, Labour and Welfare's expedited pathway for innovative medical products that are developed for Japan first or in parallel with other major markets. It came out of the Strategy of SAKIGAKE announced by MHLW in June 2014 and is run together with the Pharmaceuticals and Medical Devices Agency (PMDA). For a business development team, a designation is a useful signal: it marks a programme that Japanese regulators have already judged to be innovative, aimed at a serious condition, and likely to show prominent efficacy on early data.
Two generations of the scheme
| Scheme | Legal basis | Period | Product types |
|---|---|---|---|
| SAKIGAKE designation (pilot) | Administrative notifications | Designations made in FY2015 to FY2020 | Drugs, medical devices, in vitro diagnostics, regenerative medical products |
| Pioneering designation (先駆的医薬品等指定) | Amended Pharmaceuticals and Medical Devices Act | From 2021 onward | Drugs, medical devices, regenerative medical products |
PMDA keeps seven separate tables, one per scheme and product type, each with the applicant, the intended indication at designation, and any later approval, brand name, transfer or rescission. The tables are maintained as Japanese PDFs dated individually, so building a company-level view means reconciling all seven and translating applicant names consistently.
What a designation gives the developer
- Prioritised consultation with PMDA, with shorter waiting times for clinical trial and development advice.
- Pre-application review, letting parts of the dossier be assessed before formal submission.
- Priority review with a target total review time of around six months, compared with the standard target of about twelve months for new drugs.
- A dedicated review partner at PMDA who coordinates manufacturing, safety and review functions across the process.
Designation criteria
MHLW looks for four elements together: an innovative mechanism or approach, a serious target disease, prominent efficacy suggested by non-clinical and early clinical data, and an intention to file in Japan first or at the same time as in other regions. The last criterion is what makes the list relevant to market-entry teams: designated programmes are by definition Japan-first or Japan-parallel assets.
What the record shows
- Many designations reached approval in Japan. Examples in the PMDA tables include Xofluza (baloxavir marboxil, Shionogi) approved in February 2018, Rapalimus Gel (sirolimus, Nobelpharma) in March 2018, and Viltepso (viltolarsen, Nippon Shinyaku) in March 2020.
- Regenerative products often used conditional, time-limited approval. Stemirac (Nipro) for spinal cord injury and Delytact (G47Δ, Daiichi Sankyo) for malignant glioma were both approved with conditions and a seven-year limit.
- Academic seeds are common. The device and regenerative tables name the originating university or national centre for many products, such as Sapporo Medical University for STR01 and the National Cancer Center for the NCC Oncopanel system.
- Designations can be rescinded or transferred. The tables record withdrawals (for example pembrolizumab in gastric cancer in 2017) and transfers between companies, such as the BCX7353 designation passing from OrphanPacific through another company to BioCryst Pharmaceuticals.
How buyers use the designation record
- Partnering scans: pick out Japanese mid-size firms and venture companies that hold a designation but have no global partner for ex-Japan rights.
- Japan entry benchmarking: compare designation-to-approval times by modality to set realistic timelines for a Japan-first filing.
- Investor diligence: check whether a portfolio company's claimed Japan advantage is backed by a formal MHLW designation and whether it is still active.
A designation applies to a specific product and indication. When a company changes the indication or the development plan, the designation can lapse even though the company remains active in the field.